Parmodia tablets 0.1 mg from Japan (hyperlipidemia, dyslipidaemia)

General information about Japanese Parmodia tablets 0.1 mg 

Package details: 100 tablets

Manufacturer: Kowa Pharmaceutical, Japan.

Active ingredient: Pemafibrate (K-877), 0.1 mg in each tablet

Medical effect: Parmodia tablets 0.1 mg from Japan are effective for:

• managing atherogenic dyslipidaemia,
• treating hyperlipidemia (including familial hyperlipidemia),
• reducing remnant cholesterol and increasing HDL cholesterol (“good” cholesterol),
• lowering triglyceride levels in the blood,
• reducing apolipoprotein CIII,
• increasing serum fibroblast growth factor 21.

Contraindications and precautions: Do not use in children, elderly people (more than 65 years old), pregnant or breastfeeding women. Cannot be used for patients with liver disorder, hepatic cirrhosis, biliary atresia, renal dysfunction or cholelithiasis. If an allergic reaction occurs, discontinue use. Never use along with ciclosporin or rifampicin. When used with other drugs, be sure to consult with your doctor.

Dosage and Administration of Parmodia tablets from Japan: Take 1 tablet 2 times a day, in the morning and in the evening. The consulting doctor may adjust the dosage but the maximum of 2 tablets 2 times a day shall never be exceeded. 

Regarding the effectiveness of Parmodia tablets 0.1 mg from Japan

Parmodia tablets (pemafibrate) were approved in Japan in 2017 as an effective medicine against atherogenic dyslipidaemia and hyperlipidemia. It works as peroxisome proliferator-activated receptor alpha agonist. In other words, pemafibrate has an ability to bind to nuclear receptors. Thus, it regulates expression of targeted gene.

Despite being relatively new medicine, Parmodia tablets have already been studied by different researches and sufficient clinical trials were conducted (Hidenori Arai, Shizuya Yamashita et al. “Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial”. Journal of Atherosclerosis and Thrombosis, 2018 Jun 1; 25(6): 521–538; Shun Ishibashi, Koutaro Yokote et al. “Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial”. Journal of Clinical Lipidology, Vol. 12, Issue 1, Jan–Feb 2018, 173-184). Researches prove that pemafibrate effectively reduces “bad” cholesterol, changing it to “good” one, decreases triglyceride and apolipoprotein level in the blood (Jean-Charles Fruchart. “Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia”. Cardiovascular Diabetology, 2017, 16:124. https://doi.org/10.1186/s12933-017-0602-y ; Shizuya Yamashita, Daisaku Masuda, and Yuji Matsuzawa. “Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases”. Journal of Atherosclerosis and Thrombosis, 2019 May 1; 26(5): 389–402).